Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
Commentary|Podcasts|September 29, 2026
Supplements and Featured Publications
- Evolving Management Strategies in Systemic Mastocytosis
Dissecting Diagnostic and Management Factors in Systemic Mastocytosis
Author(s)Tracy I. George, MD
Fact checked by: Chris Ryan, Ashling Wahner
Tracy I. George, MD, discusses key factors for the diagnosis and management of systemic mastocytosis.
Advertisement
Welcome to OncLive On Air®!
OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive On Air covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we welcomed Tracy I. George, MD, who provided a pathologist’s perspective on the diagnosis and evolving management considerations for systemic mastocytosis. Dr George is president of the Innovation Business Unit and chief scientific officer at ARUP Laboratories and a professor of pathology at the Spencer Fox Eccles School of Medicine at the University of Utah in Salt Lake City.
In the exclusive interview, Dr George highlighted the key hallmarks of systemic mastocytosis that can inform diagnosis, detailed how pathologists collaborate with other multidisciplinary experts to care for patients with systemic mastocytosis, and explained how agents such as avapritinib (Ayvakit) and bezuclastinib (CGT9486) are transforming patient care.
_____
That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air.
*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.
Advertisement
Related to this article
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
Novel approaches to the use of AI in oncology may require discussion and ultimately modification of existing proprietary and regulatory barriers.
An observational analysis showed a long-term OS benefit with Orca-T in adult patients undergoing allogeneic transplantation for hematologic malignancies.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.
Advertisement
Advertisement
Trending on OncLive
1
Savolitinib Plus Osimertinib NDA Submitted to FDA for MET-Driven, EGFR-Mutated NSCLC After EGFR TKI
2
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
3
Calculating the Real Cost of False Positive Findings in Cancer Screening
4
Cilta-Cel Shows Long-Term Treatment-Free Remissions in Lenalidomide-Refractory Myeloma
5